TREE NEWS reports: China A-share innovative drug stocks fell in volatile trading, with Tonghua Jinma hitting the daily limit-down. Lummy Pharmaceutical and Innostellar Biotherapeutics dropped more than 10%, while Joinn Laboratories, Chengdu HitGen, GemPharmatech and Hongbo Pharmaceutical declined more than 6%.
China A-share innovative drug stocks fall; Tonghua Jinma hits limit-down
The breadth of the selloff—spanning contract research names, discovery platforms and biotechs rather than a single catalyst stock—points to sentiment draining from the whole innovative-drug complex rather than an isolated miss. Tonghua Jinma's limit-down matters less than the double-digit drops at Lummy and Innostellar, which suggest the market is repricing smaller, higher-beta names first. Whether this stays a one-session shakeout or marks a deeper de-risking across the sector's research-services and early-stage biotech tiers is the open question worth watching.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.